Flag of the European Union EU Clinical Trials Register Help

Clinical trials for .etr

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: .etr. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-010887-41 Sponsor Protocol Number: TMC125-TiDP2-C238 Start Date*: 2009-06-22
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combina...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013126-16 Sponsor Protocol Number: TMC125-TiDP35-C239 Start Date*: 2009-11-09
    Sponsor Name:Tibotec Pharmaceuticals c/o Tibotec BVBA
    Full Title: Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001591-33 Sponsor Protocol Number: DoRSwitch.21 Start Date*: 2022-10-06
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Open-label, single-arm, unicenter and Pilot Study of a Switch strategy from Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance
    Medical condition: Human Immunodeficiency Virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023532-16 Sponsor Protocol Number: TMC125IFD3002 Start Date*: 2012-01-26
    Sponsor Name:Janssen R&D Ireland
    Full Title: An open-label study to evaluate the safety, tolerability and pharmacokinetics of etravirine (ETR) in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infe...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-013111-35 Sponsor Protocol Number: RD.03.SPR.40099E Start Date*: 2009-12-23
    Sponsor Name:Galderma R&D SNC
    Full Title: EFFECT OF CD08514 VERSUS PLACEBO, IN PATIENTS PRESENTING WITH TYPE 1 ROSACEA, OVER AN 8-WEEK TREATMENT
    Medical condition: Moderate to severe erythematotelangiectactic rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003707-40 Sponsor Protocol Number: RD.03.SPR.40031 Start Date*: 2007-01-09
    Sponsor Name:Galderma Research and Development SNC
    Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
    Medical condition: Erythemato-Telangiectatic Rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-008655-42 Sponsor Protocol Number: TMC125VIR2038 Start Date*: 2009-03-31
    Sponsor Name:Janssen Cilag International
    Full Title: A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combinat...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) AT (Completed) DE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002057-65 Sponsor Protocol Number: RD.03.SPR.40161E Start Date*: 2011-09-01
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period.
    Medical condition: Erythematotelangiectatic rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002618-38 Sponsor Protocol Number: 721 Start Date*: 2020-06-25
    Sponsor Name:ASSOCIAZIONE "LA NOSTRA FAMIGLIA" - SEZIONE SCIENTIFICA I.R.C.C.S. "E.MEDEA"
    Full Title: Clinical trial - phase II - to test safety and efficay of Etravirine's treatment in Friedreich Ataxia's patients
    Medical condition: Friedreich's ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004243-39 Sponsor Protocol Number: VHCRP1401 Start Date*: 2016-11-17
    Sponsor Name:University of New South Wales Australia
    Full Title: A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection.
    Medical condition: Recent hepatitis C virus infection all genotypes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002933-36 Sponsor Protocol Number: ALFA-0701 Study (Mylofrance 3) Start Date*: 2007-11-02
    Sponsor Name:CH-Versailles
    Full Title: Etude de phase 3 randomisée multicentrique étudiant l’effet de l’addition de l’anticorps monoclonal Gemtuzumab Ozogamicin (Mylotarg) utilisé en doses fractionnées au traitement d’induction et de co...
    Medical condition: The standard regimen for AML is the with Mylotarg, 3 mg/m2 given on days 1,4 and 7.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002630-36 Sponsor Protocol Number: P1090 Start Date*: 2014-02-25
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) [...]
    1. The National Institute of Allergy and Infectious Diseases (NIAID)
    2. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: A PHASE I/II, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF ETRAVIRINE (ETR) IN ANTIRETROVIRAL (ARV) TREATMENT-EXPERIENCED HIV-1 INFECTED INFANT...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002221-37 Sponsor Protocol Number: PA-IT72-2012 Start Date*: 2018-11-12
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO
    Full Title: Glecaprevir/ pibrentasvir plus fixed-dose combination for 6 weeks in patients with acute hepatitis C virus: a pilot study.
    Medical condition: Acute HCV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10047457 Viral hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022092-65 Sponsor Protocol Number: ACH625-003 Start Date*: 2011-10-13
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb...
    Medical condition: Hepatitis C Virus Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10019751 Hepatitis C virus LLT
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002039-34 Sponsor Protocol Number: CABF656B2202 Start Date*: 2008-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed) GR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000178-36 Sponsor Protocol Number: VHCRP1309 Start Date*: 2016-04-28
    Sponsor Name:University of New South Wales
    Full Title: A phase II, open-label, single arm, multicentre, international trial of sofosbuvir and GS-5816 for people with chronic hepatitis C virus infection and recent injection drug use
    Medical condition: Chronic hepatitis C all genotypes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000828-24 Sponsor Protocol Number: ANRS163ETRAL Start Date*: 2015-05-31
    Sponsor Name:Inserm-ANRS
    Full Title: A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with a...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005385-12 Sponsor Protocol Number: GI-5005-02 Start Date*: 2008-04-11
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis ...
    Medical condition: The genotype 1 Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057212 Hepatitis viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003562-90 Sponsor Protocol Number: VHCRP1405 Start Date*: 2016-06-17
    Sponsor Name:The Kirby Institute - UNSW Australia
    Full Title: A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and...
    Medical condition: Chronic hepatitis C virus genotype 1 infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10072844 Hepatitis C virus genotype 1a positive LLT
    19.0 100000004848 10072845 Hepatitis C virus genotype 1b positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005083-26 Sponsor Protocol Number: RD.03.SPR.40225E Start Date*: 2014-02-28
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea
    Medical condition: Flushing related to erythematotelangiectatic or papulopustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10016825 Flushing PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 10:03:18 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA